Methylene Blue Protocol
Methylene blue is a prescription drug.
35/100
Various researchers (Francisco Gonzalez-Lima and others)
Decided with your clinician
9 phases
2 conditions
Protocol Overview
Methylene blue is a prescription drug. As an IV hospital treatment it is FDA-approved for acquired methemoglobinemia. Low oral doses are being studied off-label for memory and mitochondrial function; human evidence so far is small and early. A licensed clinician decides whether it fits and the dose.
Used For
Key Resources
Safety Profile
FDA-approved in 2016 as an IV injection for acquired methemoglobinemia, with a boxed warning for serotonin syndrome when combined with serotonergic drugs. Small human studies, such as a single-dose brain imaging study in healthy adults (Rodriguez 2016), suggest effects on memory-related brain activity; larger trials are needed. Antiviral effects have been seen in lab studies but are not established in people, and an infection needs proper medical care. Anyone considering it works with a licensed clinician.
Find a Practitioner
Gabriel can find and book a practitioner who works with this approach.
Book with GabrielAbout Evidence Score
The Evidence Score (0 to 100) rates the strength of evidence from studies in people for the uses listed: higher means stronger, more consistent research. It does not measure safety. It is not medical advice.
For education, not medical advice. Talk with a licensed clinician before you start, and never stop or change a prescribed medication without your prescriber.